VivoSeq
Oncology

Non-Muscle Invasive Bladder Neoplasms

4

Pipeline Programs↗

4

Active Trials↗

2

Companies Involved↗

Non-Muscle Invasive Bladder Neoplasms is an early-stage landscape with 4 programs across 2 companies. The most active players are Johnson & Johnson, Gynecologic Oncology Group. 4 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Johnson & Johnson logo

Johnson & Johnson

4 programs

Phase 3G

Gynecologic Oncology Group

1 program

Phase 3

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 2
No programs
Phase 34

TAR-210

Johnson & Johnson

Mitomycin C

Gynecologic Oncology Group

Gemcitabine

Johnson & Johnson

TAR-200

Johnson & Johnson

Approved
No programs

Analysis

Trial Status

5

clinical trials

Recruiting3 · 60%
Active, not recruiting1 · 20%
Approved for marketing1 · 20%

Clinical Trials

Trial Activity

17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06211764·272 enrolled
A Phase 3, Randomized Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Single Agent Intravesical Chemotherapy in Participants With Intermediate-risk Non-muscle Invasive Bladder Cancer (IR-NMIBC) and Susceptible FGFR Alterations
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06319820·641 enrolled
Pre-Approval Access US Intermediate Size Expanded Access Protocol for TAR-200 Treating Physician Use
Approved for marketing·Johnson & Johnson logoJohnson & Johnson·N/A·NCT06877676
A Phase 3, Randomized, Open-label, Multicenter Study Evaluating the Efficacy and Safety of TAR-210 Erdafitinib Intravesical Delivery System Versus Investigator's Choice of Intravesical Chemotherapy in Participants With High-risk Non-muscle-invasive Bladder Cancer With Susceptible FGFR Alterations Who Had Received Intravesical Bacillus Calmette-Guérin (BCG)
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 3·NCT06919965·220 enrolled
A Multicenter, Prospective, Longitudinal Study to Assess Real-World Use and Outcomes After the Launch of TAR-200 for NMIBC in the US
Recruiting·Johnson & Johnson logoJohnson & Johnson·N/A·NCT07309445·150 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)